1
|
Mishra A, Dongre S, Kulkarni G, Deshmane R, Thappa D, Ghade N, Lona J, Kokatam S, Deo A, Sonar S, Krishnan A. Comparative assessment of immunogenicity of recombinant insulin Aspart from BioGenomics and its originator NovoRapid® in adult patients with type 2 diabetes mellitus. J Endocrinol Invest 2023:10.1007/s40618-023-02263-5. [PMID: 38147290 DOI: 10.1007/s40618-023-02263-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Accepted: 11/28/2023] [Indexed: 12/27/2023]
Abstract
OBJECTIVES To assess and compare the immunogenicity of recombinant Insulin Aspart [manufactured by BioGenomics Limited (BGL-ASP)] with its originator NovoRapid® (manufactured by Novo Nordisk) in adult patients with type 2 diabetes mellitus. RESEARCH DESIGN AND METHODS BGL-IA-CTP301 study was a randomized, open label, parallel group, multicenter phase-III clinical study to compare the efficacy and safety of recombinant Insulin Aspart 100 U/mL [manufactured by BioGenomics Limited (BGL-ASP)] with its reference medicinal product (RMP); NovoRapid® [manufactured by Novo Nordisk], in adult patients with Type 2 diabetes mellitus (T2DM). The primary objective of the study was to compare the immunogenicity of BGL-ASP and RMP; NovoRapid® in patient serum samples collected from phase-III clinical study. Immunogenicity was studied as the incidence of patients positive for anti-insulin Aspart (AIA) antibodies, developed against BGL-ASP/RMP at baseline, end of 12 week and end of 24 week of the treatment period. The changes in incidence of patients positive for AIA antibodies post-baseline were also studied to assess and compare the treatment-emergent antibody response (TEAR) between the treatment groups (BGL-ASP and RMP). Statistical evaluation was done by Fisher's exact test to compare the overall incidence of patients positive for AIA antibodies and the TEAR positives observed post-baseline in both the treated groups. An in-vitro neutralizing antibody assay (Nab assay) was also performed to study the effect of AIA antibodies in neutralizing the biological activity/metabolic function of the insulin. The neutralizing potential of AIA was studied by its effect on %glucose uptake. We also evaluated the association between AIA antibody levels and its impact on biological activity by studying the correlation between them. RESULTS Analysis of immunogenicity data suggested that the percentage of patients positive for AIA antibodies until week 24 was similar and comparable in both the treatment groups, BGL-ASP and RMP; NovoRapid®. The changes in incidence of patients positive for AIA post-baseline in terms of TEAR positives were also similar and comparable between the treatment groups. The results of the Nab assay with confirmed positive AIA samples from BGL-ASP- and RMP-treated groups did not have any negative impact on %glucose uptake by the cells in Nab assay, confirming the absence of neutralizing antibodies in both the treatment groups. The correlation studies also showed absence of association between AIA antibody levels and percentage glucose uptake in both BGL-ASP and RMP-NovoRapid® treatment groups. CONCLUSIONS: The immunogenicity assessment based on the overall incidence of patients positive for AIA, changes in incidence of patients positive for AIA post-baseline, TEAR rates and absence of neutralizing antibodies, were found to be apparently similar and comparable in both the treatment groups (BGL-ASP and RMP). We conclude from our studies that the immunogenicity of BGL-ASP is similar and comparable to RMP and the observed immunogenicity in terms of anti-insulin Aspart antibody levels had no impact on the biological activity of insulin.
Collapse
Affiliation(s)
| | | | | | | | | | - N Ghade
- BioGenomics Ltd, Thane, India
| | - J Lona
- BioGenomics Ltd, Thane, India
| | | | - A Deo
- BioGenomics Ltd, Thane, India
| | - S Sonar
- BioGenomics Ltd, Thane, India
| | | |
Collapse
|
2
|
Vashistha N, Deo A, Singhal D. Gastrointestinal: Mucocele appendix with atypical "volcano sign". J Gastroenterol Hepatol 2022; 37:45. [PMID: 34053128 DOI: 10.1111/jgh.15541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/03/2021] [Revised: 04/17/2021] [Accepted: 05/07/2021] [Indexed: 12/09/2022]
Affiliation(s)
- N Vashistha
- Department of Surgical Gastroenterology, Max Superspeciality Hospital, Saket, New Delhi, India
| | - A Deo
- Department of Gastroenterology and Hepatology, Max Superspeciality Hospital, Saket, New Delhi, India
| | - D Singhal
- Department of Surgical Gastroenterology, Max Superspeciality Hospital, Saket, New Delhi, India
| |
Collapse
|
3
|
Rajappa S, Joshi A, Doval DC, Batra U, Rajendranath R, Deo A, Biswas G, Bajpai P, Tilak TVS, Kane S, Kumar K, Kumar M, Talele AD, Devde P, Gupta A, Joshi N, Sejpal J, Bunger D, Khan M. Novel formulations of docetaxel, paclitaxel and doxorubicin in the management of metastatic breast cancer. Oncol Lett 2018; 16:3757-3769. [PMID: 30127986 PMCID: PMC6096158 DOI: 10.3892/ol.2018.9057] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2017] [Accepted: 05/24/2018] [Indexed: 12/17/2022] Open
Abstract
The management of breast cancer with advanced disease or metastasis is a common problem in India and other countries. A panel of 13 oncology experts deliberated on the sidelines of the 35th Indian Cooperative Oncology Network Conference held in Mumbai to formulate an expert opinion recommendation on the novel drug delivery system (NDDS) formulations in the treatment of metastatic breast cancer (MBC). The survey comprised of 39 questions related to limitations of conventional formulations and therapeutic positioning of NDDS formulations of docetaxel, paclitaxel and doxorubicin in the management of MBC. The experts used data from published literature and their practical experience to provide expert opinion and recommendations for use by the community oncologists. The experts opined that the newer NDDS formulations should provide a significant efficacy advantage in terms of overall survival and progression-free survival, or demonstrate better tolerability when compared with conventional formulations. The newer NDDS formulations of taxanes should be considered in special circumstances such as diabetes, in patients who have had hypersensitivity reactions and in cases where steroids need to be avoided. The novel formulations of doxorubicin should be used in the elderly and in patients with borderline cardiac function.
Collapse
Affiliation(s)
- Senthil Rajappa
- Department of Medical Oncology, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, Telangana 500034, India
| | - Ashish Joshi
- Nanavati Hospital, Mumbai, Maharashtra 400056, India
| | - Dinesh C Doval
- Rajiv Gandhi Cancer Institute and Research Centre, Delhi 110085, India
| | - Ullas Batra
- Rajiv Gandhi Cancer Institute and Research Centre, Delhi 110085, India
| | | | - Avinash Deo
- Fortis SL Raheja Hospital, Mumbai, Maharashtra 400016, India
| | | | - Peush Bajpai
- Max Super Speciality Hospital, New Delhi 110017, India
| | - T V S Tilak
- Command Hospital, Bangalore, Karnataka 560007, India
| | - Sriram Kane
- Kane Hematology and Oncology Clinic, Nagpur, Maharashtra 440012, India
| | - Kishore Kumar
- Command Hospital, Bangalore, Karnataka 560007, India
| | - Manish Kumar
- Command Hospital, Lucknow, Uttar Pradesh 226002, India
| | | | - Prakash Devde
- Seth Nandlal Dhoot Hospital, Aurangabad, Maharashtra 431210, India
| | - Ashutosh Gupta
- Government Medical College, Jammu, Jammu and Kashmir 180001, India
| | - Nisarg Joshi
- Intas Pharmaceuticals Ltd., Ahmedabad, Gujarat 380061, India
| | - Jaykumar Sejpal
- Intas Pharmaceuticals Ltd., Ahmedabad, Gujarat 380061, India
| | - Deepak Bunger
- Intas Pharmaceuticals Ltd., Ahmedabad, Gujarat 380061, India
| | - Mujtaba Khan
- Intas Pharmaceuticals Ltd., Ahmedabad, Gujarat 380061, India
| |
Collapse
|
4
|
Choudhary PK, Koirala A, Rimal HS, Deo A. Cytomorphological study of palpable breast lumps. J Pathol Nep 2015. [DOI: 10.3126/jpn.v5i10.15633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Background: Breast lump is a very common clinical presentation for which fine needle aspiration cytology is often sought for. Because of it’s significant diagnositic value, FNAC has become a routine tool in the evaluation of the nature of the lesion. The objective of this study was to determine the cytomorphological patterns of breast lump in eastern part of Nepal among individuals attending Nobel Medical College. Materials and Methods: This was a retrospective descriptive study done in department of pathology from December 2012 to June 2015. All individuals presenting with breast lumps was included in this study. FNAC was done as per standard procedure and categorized as per United Kingdom National Health Survey Breast Screening Programme (UK-NHS-BSP) categories and further also categorized in to neoplastic and non-neolastic categories. Results: We studied 771 cases of breast lumps. Occurrence of breast lump was more common in female (97.4%). Neoplastic lesions accounted for 84.1% of cases out of which benign comprised of 94.6% and malignant comprised of 5.6%. Common benign lesions observed were that of fibroadenona (264) and fibrocystic changes (204). Ductal carcinoma was the most common malignant lesions. All malignant lesions were observed in older age and female sex population.Conclusion: Most of the cases of breast lumps are benign in nature and very few accounted for malignant cases. There is predominance of benign lesions in young age and increased malignancy in older age and female population.
Collapse
|
5
|
Dugo C, Alsamarra’i A, Rigolli M, Deo A, Dyer J, Christiansen J, Whalley G. A clinical audit of in-hospital echocardiography in heart failure. Heart Lung Circ 2015. [DOI: 10.1016/j.hlc.2015.04.089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
6
|
Alsamarra’i A, Dugo C, Rigolli M, Deo A, Dyer J, Christiansen J, Whalley G. The impact of age, clinical status, and population demographics on length of stay associated with heart failure admissions: A comparison of two hospitals. Heart Lung Circ 2015. [DOI: 10.1016/j.hlc.2015.04.088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
9
|
Deo A, Mehta HG, Biniyala R, Pathare S, Mehta PJ, Mehtalia SD. Proximal myopathy associated with griseofulvin therapy. J Assoc Physicians India 1994; 42:85. [PMID: 7836265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
10
|
Deo A, Mehta HG, Pathare S, Biniyala R, Mehta PJ, Mehtalia SD. Spontaneous reversal of atropine induced delirium in organophosphorus compound poisoning: an early sign of re-excretion. J Assoc Physicians India 1993; 41:611. [PMID: 8307927] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Affiliation(s)
- A Deo
- BYL, Nair Hospital, Bombay
| | | | | | | | | | | |
Collapse
|